Chemomab Therapeutics Ltd. (CMMB) Key Metrics
CMMB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $9.3M
- Enterprise value
- $6.3M
- P/E (TTM)
- —
- Forward P/E
- 12.9
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.9 10-yr median 0.9
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 0.74
CMMB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCMMB valuation Price multiples at each fiscal year-end price.
Price / book
0.9
2025 · hover or tap a bar for each year
20162025
Free cash flow yield
−106.6%
2025 · hover or tap a bar for each year
20162025
CMMB returns How much profit the business earns on the capital it uses.
Return on equity+21.8 pts
−69.5%
2025 · hover or tap a bar for each year
20162025
Return on assets+12.8 pts
−58.5%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
CMMB per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$1.41
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.76
2025 · hover or tap a bar for each year
20162025
Book value per share
$1.93
2025 · hover or tap a bar for each year
20162025
Shares outstanding
6.4M
2025 · hover or tap a bar for each year
20162025
CMMB financial health Debt, liquidity and how easily interest is covered.
Net debt+$3.6M
−$10.4M
2025 · hover or tap a bar for each year
20162025
Current ratio+82.2%
9.08
2025 · hover or tap a bar for each year
20162025
CMMB efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−1,046 days
2,892 days
2025 · hover or tap a bar for each year
20162025
CMMB valuation history
Fiscal year-endToday10-year median
CMMB returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CMMB debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CMMB cash returned to shareholders
DividendsBuybacksFree cash flow
CMMB price vs earnings per share
Share price at year-endEPS (right axis)
CMMB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $10.5M | — | $6.0M | $36.4M | $71.6M | — | — | — | — | — |
| Enterprise value | $157,607 | — | −$13.4M | −$3.3M | $10.8M | — | — | — | — | — |
| Price / book | 0.9 | — | 0.4 | 1.0 | 1.2 | — | — | — | — | — |
| Earnings yield | −85.5% | — | −404.2% | −75.9% | −17.4% | — | — | — | — | — |
| Free cash flow yield | −106.6% | — | −393.0% | −55.9% | −17.6% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 3.3% | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $1.65 | $7.24 | $2.04 | $12.80 | $27.60 | $110.72 | $89.60 | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$1.41 | — | −$8.25 | −$9.72 | −$4.81 | — | — | — | — | — |
| Operating cash flow per share | −$1.76 | — | −$8.02 | −$7.13 | −$4.77 | — | — | — | — | — |
| Free cash flow per share | −$1.76 | — | −$8.02 | −$7.16 | −$4.87 | — | — | — | — | — |
| Cash per share | $1.63 | — | $6.74 | $14.02 | $23.58 | — | — | — | — | — |
| Book value per share | $1.93 | — | $5.79 | $12.73 | $23.70 | — | — | — | — | — |
| Tangible book value per share | $1.93 | — | $5.78 | $12.73 | $23.70 | — | — | — | — | — |
| Capex per share | $0.00 | — | $0.00 | $0.02 | $0.09 | — | — | — | — | — |
| Debt per share | — | — | $0.13 | $0.08 | $0.13 | — | — | — | — | — |
| Shares outstanding | 6.4M | — | 2.9M | 2.8M | 2.6M | — | — | — | — | — |
| Change in shares outstanding | — | — | +3.3% | +9.7% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −69.5% | −91.3% | −91.0% | −56.6% | −34.6% | −100.9% | 244.6% | 288.8% | — | −174.1% |
| Return on invested capital (ROIC) | −967.1% | — | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −58.5% | −71.3% | −74.3% | −51.5% | −32.5% | −72.5% | 166.8% | 178.9% | −253.5% | −103.3% |
| Return on tangible assets | −65.2% | −82.3% | −109.4% | −64.2% | −19.4% | −93.7% | 137.3% | 104.1% | −469.9% | −83.8% |
| Income quality (OCF / net income) | — | — | — | — | — | — | −0.61 | −1.07 | — | — |
| Financial health | ||||||||||
| Total debt | — | $324,000 | $392,000 | $214,000 | $343,000 | $607,000 | $586,000 | — | — | — |
| Cash & short-term investments | $10.4M | $14.3M | $19.8M | $39.9M | $61.2M | $11.7M | $17.6M | $7.5M | $1.5M | $4.6M |
| Net debt | −$10.4M | −$13.9M | −$19.4M | −$39.7M | −$60.8M | −$11.1M | −$17.0M | −$7.5M | −$1.5M | −$4.6M |
| Debt / equity | — | 0.02 | 0.02 | 0.01 | 0.01 | 0.06 | 0.05 | — | — | — |
| Debt / assets | — | 0.02 | 0.02 | 0.00 | 0.01 | 0.05 | 0.03 | — | — | — |
| Net debt / EBITDA | — | — | — | — | — | — | −0.63 | −0.59 | — | — |
| Current ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 | 9.00 | 4.42 | 3.98 | 0.59 | 2.07 |
| Quick ratio | 9.08 | 4.98 | 4.53 | 6.18 | 24.16 | 9.50 | 4.42 | 4.00 | 0.59 | 2.07 |
| Interest coverage | — | — | — | -80.8 | -111.4 | — | 6.4 | — | — | — |
| Working capital | $11.9M | $12.8M | $16.1M | $35.0M | $60.0M | $10.5M | $14.1M | $8.2M | −$1.1M | $2.5M |
| Invested capital | $2.0M | −$405,000 | −$2.4M | −$3.5M | $648,000 | −$289,000 | −$4.6M | $2.3M | −$2.1M | −$1.3M |
| Tangible asset value | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M | $10.8M | $14.9M | $9.8M | −$609,000 | $3.3M |
| Net current asset value | $11.9M | $12.6M | $15.7M | $34.9M | $59.8M | $10.2M | $13.4M | $8.0M | −$1.1M | $2.5M |
| Graham net-net per share | $1.75 | — | $4.88 | $11.74 | $22.26 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | $0 | $0 | $1.2M | $0 | — | — | — | — | — |
| Capex / depreciation | 0.04 | 0.00 | 0.04 | 1.17 | 7.03 | 0.42 | 0.34 | 3.23 | 0.67 | 1.87 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | -3,554.0 | -5,664.0 | — | -10,755.0 | -1,489.6 | -50.4 | -425.8 | — | 0.0 |
| Days payables outstanding | 2,891.8 | 3,937.8 | 6,019.0 | 9,552.6 | 7,665.2 | 267.3 | 273.4 | 1,537.4 | 953.8 | 3,126.0 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.13 | 0.09 | 0.06 | 0.04 | 0.05 | 1.37 | 1.33 | 0.24 | 0.38 | 0.12 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 40,638.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.7M | $276,000 | $374,000 | $319,000 | $126,500 | $355,000 | $2.0M | $1.7M | $113,504 | $134,397 |
| Average payables | $558,996 | $574,500 | $1.1M | $1.5M | $714,500 | $59,000 | $210,498 | $277,998 | $133,266 | $348,044 |
| Average inventory | — | −$518,502 | −$1.0M | — | −$1.0M | −$328,771 | −$38,771 | −$77,000 | — | $1 |
| Intangibles / total assets | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CMMB's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CMMB valuation and financial ratios
Chemomab Therapeutics earned a return on equity of −69.5% and a return on invested capital of −967.1% in fiscal 2025.
See the CMMB income statement, the CMMB chart for price history, or the CMMB stock overview for the latest quote and news.
CMMB key metrics FAQ
What is Chemomab Therapeutics's return on equity?
Chemomab Therapeutics's return on equity (ROE) was −69.5% in fiscal 2025: net income of -$9.0 million on average shareholders' equity of $12.9 million.
What is Chemomab Therapeutics's ROIC?
Chemomab Therapeutics's return on invested capital was −967.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Chemomab Therapeutics's free cash flow yield?
Chemomab Therapeutics generated -$11.2 million of free cash flow in fiscal 2025, a free cash flow yield of −106.6% on its market value at year-end ($10.5 million).
What is Chemomab Therapeutics's current ratio?
Chemomab Therapeutics's current ratio was 9.08 at the end of fiscal 2025: current assets were 9.08 times current liabilities.